




INTEGRATED SERVICE

FOR ANTIBODY DRUG DISCOVERY

ONE STOP INTEGRATED SERVICE FOR ANTIBODY DRUG DISCOVERY FROM TARGET TO CANDIDATE SELECTION


- Comprehensive biology capability for target validation
- Integrated multiple platforms supporting reagent generation, assay development, and bioanalytical analysis
- Featured hybridoma and phage display platform for antibody lead candidate generation
- Strong antibody engineering asset for candidate optimization
- Built-in manufacturability and efficacy service connecting antibody discovery to CMC
- Extensive experience in managing and successfully delivering more than 60 projects

INTEGRATED ANTIBODY DRUG DISCOVERY TYPICAL FLOW CHART



PHASE I: ANTIBODY LEAD CANDIDATE GENERATION

- Both hybridoma and phage display platforms were used for antibody generation
- Functional assays were developed and adapted for early screening to identify potential functional candidates



PHASE II: ANTIBODY ENGINEERING AND CANDIDATE SELECTION

- Multiple panels of sequence analysis were employed to reduce potential liabilities
- Optimized candidates were extensively characterized by a variety of bio-functional and analytical assays
- Manufacturability test were integrated to ensure late stage development
- Efficacy and PK profiling were included for candidate selection

